Cube Labs is redefining the intersection of science and entrepreneurship through its venture-building model, designed to create scalable, market-ready healthcare companies. Founded by a fifth-generation medical doctor, the company transitions cutting-edge academic research into viable businesses, bypassing traditional incubator and venture capital routes. As the first and only listed venture builder in Italy, Cube Labs joined the Euronext Growth Milan Pro segment in March 2023, achieving a market capitalisation of €34.1mn. Its end-to-end approach involves full ownership and operational control of portfolio companies, currently numbering 17, and includes partnerships with over 700 researchers and 88 academic institutions. The firm’s strategy centres on risk-bearing company creation, early-stage capital provision, and support in intellectual property, regulatory affairs, and commercialisation. With a strong emphasis on democratising healthcare, Cube Labs blends science, artificial intelligence, and fintech to broaden access and reduce barriers across both primary and emerging markets. Its AI capabilities serve as core drivers of productivity rather than auxiliary tools, reflecting a forward-thinking stance on the role of hybridised technologies in life sciences. The company’s global expansion spans Europe, North America, and Asia, underpinned by strategic alliances, including with India’s Modi Global Enterprises. Cube Labs has generated notable portfolio value increases and is recognised for its contribution to healthcare commercialisation. Transparent capital sourcing, ESG principles, and a focus on accessibility place the company at the forefront of systemic healthcare innovation. CFI.co Judging Panel congratulates Cube Labs on winning the 2025 award for Champion of Scalable Market-Ready Healthcare Ventures (Italy).